CytoDyn (OTCQB:CYDY) is a classic boom bust stock. Its fanboys are convinced that its leronlimab will become the next powerhouse HIV therapy, not to mention cancer, NASH etc. Others such as myself, on most days not so much, per earlier articles here and here.
I feel that CytoDyn has promoted its book so enthusiastically that it is worthwhile to consider a more skeptical view. I have been slow in completing this article; events are overtaking me per a CytoDyn presentation this afternoon (2/6/20) to discuss the following:
- Status of filing the Biologics